Roisin McGuigan, Editor, Immuno-Oncology Insights, speaks to Pedro Correa de Sampaio, CEO and co-founder, Neobe Therapeutics, about his work utilizing the field of synthetic biology to engineer ‘bacterial trojan horses’ to overcome biophysical barriers to cancer immunotherapy efficacy.
